Decision: Favourable
Study Title:
Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA.
NREC Code:
21-NREC-CT-038-NPC
Decision:
Favourable
Meeting Date:
21/07/2021
Study Type:
CT application
Principal Investigator:
Professor Patrick Morris
PI Institution:
Beaumont Hospital
Sponsor:
Cancer Trials Ireland